Formulation Considerations and Application of Nanostructured Lipid Carriers (NLC) for Ocular Delivery

被引:1
|
作者
Kumari, Shilpa [1 ]
Jaiswal, Sandhya [1 ,3 ]
Kamboj, Anjoo [2 ]
机构
[1] IKGPTU, Chandigarh Coll Pharm, Dept Pharmaceut, Mohali, Punjab, India
[2] IKGPTU, Chandigarh Coll Pharm, Dept Pharmaceut Chem, Mohali, Punjab, India
[3] IKGPTU, Chandigarh Coll Pharm, Dept Pharmaceut, Mohali 140307, Punjab, India
关键词
Fungal infection; Ocular delivery; Nanostructured lipid carriers; Barriers; OPHTHALMIC DRUG-DELIVERY; IN-VITRO EVALUATION; NANOPARTICLES SLN; FUNGAL; INFECTIONS; SYSTEMS; EYE; PERSPECTIVES; CLOTRIMAZOLE;
D O I
10.5530/jyp.2023.15.57
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fungal infection associated with eye annually affects more than one ten lakh people globally. It can affect vision and sometimes causes complete blindness. Drug delivery through ocular route has always been a challenge, as in the eye numerous barriers are located in conjunctiva, cornea, iris-ciliary body and retina which prevents drug dose from reaching the site resulting into low bioavailability of drug. Treatment through conventional dosage form often possess disadvantage of low retention time of drug as they are flows out from the corneal cavity by tear flow and nasal drainage. To overcome these challenges, the need of the hour is to fabricate a novel drug delivery system that would overcome the barrier channels of eye and could results into enhanced drug absorption at its site of action. Till date numerous technologies viz. Nanoparticles, Nanostructured technologies can overcome the barriers located in the eye and improve bioavailability of drugs. The present review highlights about nanostructured lipid carriers and their potential use in ocular delivery. The aim is to study nanostructured lipid carriers as nanocarriers to increase the permeability, solubility, bioavailability and retention time of active pharmaceutics agents through ocular administration. High-pressure homogenization, emulsification-solvent evaporation and micro-emulsion are some of the methods by which they can be prepared. So, it is concluded that nanostructured lipid carriers represent a potential nanocarrier for the reliable delivery of drugs to the ocular tissues with increased solubility, bioavailability and residence time.
引用
收藏
页码:419 / 429
页数:11
相关论文
共 50 条
  • [21] Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC)
    Fang, Jia-You
    Fang, Chia-Lang
    Liu, Chi-Hsien
    Su, Yu-Han
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2008, 70 (02) : 633 - 640
  • [22] PEGylated nanostructured lipid carriers (PEG-NLC) as a novel drug delivery system for biochanin A
    Wang, Lei
    Luo, Qing
    Lin, Tongyuan
    Li, Rui
    Zhu, Tingting
    Zhou, Kai
    Ji, Zhaojie
    Song, Jiawei
    Jia, Buyun
    Zhang, Caiyun
    Chen, Weidong
    Zhu, Guangyu
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2015, 41 (07) : 1204 - 1212
  • [23] Formulation development and evaluation of nanostructured lipid carriers for topical delivery of honokiol
    Podaralla, Satheesh K.
    Averineni, Ranjith
    Perumal, Omathanu
    Dwivedi, Chandradhar
    CANCER RESEARCH, 2012, 72
  • [24] Formulation and optimization of Agomelatine loaded nanostructured lipid carriers for intranasal delivery
    Salvankar, Shailendra
    Thite, Komal
    Ratnaparkhi, Mukesh
    Kulkarni, Gajanan
    JOURNAL OF RESEARCH IN PHARMACY, 2024, 28 (05): : 1592 - 1608
  • [25] Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art
    Weber, S.
    Zimmer, A.
    Pardeike, J.
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2014, 86 (01) : 7 - 22
  • [26] Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir
    Seyfoddin, Ali
    Al-Kassas, Raida
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2013, 39 (04) : 508 - 519
  • [27] Rheology of nanostructured lipid carriers (NLC®) suspended in a viscoelastic medium
    Souto, EB
    Gohla, SH
    Müller, RH
    PHARMAZIE, 2005, 60 (09): : 671 - 673
  • [28] Development of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application
    Nnamani, Petra O.
    Hansen, Steffi
    Windbergs, Maike
    Lehr, Claus-Michael
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2014, 477 (1-2) : 208 - 217
  • [29] Development of an Itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application
    Pardeike, J.
    Weber, S.
    Haber, T.
    Wagner, J.
    Zarfl, H. P.
    Plank, H.
    Zimmer, A.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2011, 419 (1-2) : 329 - 338
  • [30] Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies
    Elmowafy, Mohammed
    Al-Sanea, Mohammad M.
    SAUDI PHARMACEUTICAL JOURNAL, 2021, 29 (09) : 999 - 1012